Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999
about
Marine Natural Products as Models to Circumvent Multidrug ResistanceDisrupting P-glycoprotein function in clinical settings: what can we learn from the fundamental aspects of this transporter?The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactionsRole of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer.Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance.Inhibition of breast cancer resistance protein (ABCG2) in human myeloid dendritic cells induces potent tolerogenic functions during LPS stimulationMolecular pathways: regulation and therapeutic implications of multidrug resistanceRepositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug ResistanceDevelopment of a cyclin-dependent kinase inhibitor devoid of ABC transporter-dependent drug resistanceABC transporters: unvalidated therapeutic targets in cancer and the CNSCell signaling-based classifier predicts response to induction therapy in elderly patients with acute myeloid leukemiaAnalysis of the interaction of induction regimens with p-glycoprotein expression in patients with acute myeloid leukaemia: results from the MRC AML15 trial.Drug Repurposing from an Academic Perspective.Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice.Drug resistance: still a daunting challenge to the successful treatment of AML.CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900.In vitro and in vivo downregulation of the ATP binding cassette transporter B1 by the HMG-CoA reductase inhibitor simvastatinIdentification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1The Role of Multidrug Resistance Efflux Pumps in Cancer: Revisiting a JNCI Publication Exploring Expression of the MDR1 (P-glycoprotein) Gene.Treatment of acute myeloid leukemia with 20-30% bone marrow blasts.ABCG2 is not able to catalyze glutathione efflux and does not contribute to GSH-dependent collateral sensitivity.The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanismsDelivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.Unfavorable-risk cytogenetics in acute myeloid leukemia.The effect and clinical consequences of hypoxia on cytochrome P450, membrane carrier proteins activity and expression.Upfront therapy of acute myeloid leukemia.The controversial role of ABC transporters in clinical oncology.New agents for acute myeloid leukemia: is it time for targeted therapies?Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?Acute myeloid leukemia in older adults.Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?Importance of detecting multidrug resistance proteins in acute leukemia prognosis and therapy.Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients.Natural product modulators to overcome multidrug resistance in cancer.Itraconazole and clarithromycin inhibit P-glycoprotein activity in primary human sinonasal epithelial cells.Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials.Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies.The therapeutic potential of targeting ABC transporters to combat multi-drug resistance.Neither P-gp SNP variants, P-gp expression nor functional P-gp activity predicts MDR in a preliminary study of plasma cell myeloma.Phenolic indeno[1,2-b]indoles as ABCG2-selective potent and non-toxic inhibitors stimulating basal ATPase activity.
P2860
Q26741330-084FFE7A-82AF-4862-A68A-E1DBBB4DC331Q28069761-8D7A384A-97F3-49C4-A2E8-996BCB80FEF0Q28535342-F72A3481-B68D-4C4E-9439-68582A9D7B42Q30274798-6C3AD37C-AB70-4F67-B714-E3EE38077494Q33763765-23DE3E94-178A-4683-9B86-6F70F83191D2Q34027988-9503D164-E1B4-4E92-8A33-D7A7BE6350A5Q34255292-EFD16CF1-0B9E-4712-BC18-02687ADC0589Q34774854-7D5F0BA5-E88F-49FB-8F54-B4277C0DEA2FQ35000329-3C709F40-3558-45C1-9B2E-7C3ED731C045Q35056738-6DE4F25A-4555-4E5A-AEF0-6595F87979B1Q35462617-19332D51-CEF3-4095-8DD6-5F07E77A918DQ35664332-DF56110D-A6A2-499E-8973-55794B7693DBQ35774211-D07B5501-A426-45E8-9692-68B90DD85722Q35800831-2D8E9CF5-30B6-4D13-AAE3-C9589800BABEQ35946969-CD6F7D42-6FD8-4B04-B6BE-1425F6627E02Q36249453-28316B4E-BE5F-4847-B589-B8ADA56C763BQ36427010-346D7D9F-2118-4CAA-AD0A-98307BBF5C1EQ36717999-5A0F0DE4-03D7-4852-A26C-D340E5094FA2Q36812960-2589879C-0C69-4484-AFB3-9FD411732D22Q36934199-6541354D-AE53-4BE5-A9C4-F9597C6FC615Q37285224-EF3D0122-50D0-49EB-BAE5-052AB1AE53CEQ37289700-0A2660F1-7DFF-411E-BF3F-9DE6214825B2Q37308322-646108FE-DDC9-41AC-8402-9A22EC063E3FQ37865545-CF6B9B0B-D805-4BB8-82BC-641DA7454520Q37880895-F39444A9-0EEF-4114-B4FA-E7BF849A2626Q37897183-AB5A1A4E-6FB0-4ECD-94D4-7213A00DADD4Q37941758-693B67D4-D8F2-4BEE-B4A9-4D717A6BB677Q37973135-4962C202-E925-491D-8DC6-A217F8E68157Q37978341-5A8896F6-E861-48BB-8BDB-4CFF3458B04DQ38026008-ED021011-6010-42A1-940B-19D94B32100DQ38055067-84DB690E-1A22-4C50-9415-AD4B8CAC26A7Q38071981-2EEA44BD-BBE9-4F1E-A1CF-AB6CB6FBCF22Q38161965-59F52188-0686-4834-8855-5C9AA2E63923Q38343461-C5AE8EE4-49D9-43F1-8533-B6D36965FB9EQ38439349-387E8853-F804-448D-BEFB-BAB1E3034524Q38760193-47F3401F-092B-4251-92E4-CF117445861BQ38856951-09066A5A-497D-4D66-9F45-36A02F436EF5Q39196784-11CA17DB-4F95-4DC8-BF64-7EF9672899D2Q39638448-B25B42B8-95FE-4DD2-AA83-D3D8F5410803Q41138386-7B5EFF1C-6718-445D-9456-939D51059554
P2860
Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Zosuquidar, a novel modulator ...... ooperative Oncology Group 3999
@ast
Zosuquidar, a novel modulator ...... ooperative Oncology Group 3999
@en
Zosuquidar, a novel modulator ...... ooperative Oncology Group 3999
@nl
type
label
Zosuquidar, a novel modulator ...... ooperative Oncology Group 3999
@ast
Zosuquidar, a novel modulator ...... ooperative Oncology Group 3999
@en
Zosuquidar, a novel modulator ...... ooperative Oncology Group 3999
@nl
prefLabel
Zosuquidar, a novel modulator ...... ooperative Oncology Group 3999
@ast
Zosuquidar, a novel modulator ...... ooperative Oncology Group 3999
@en
Zosuquidar, a novel modulator ...... ooperative Oncology Group 3999
@nl
P2093
P2860
P921
P1433
P1476
Zosuquidar, a novel modulator ...... ooperative Oncology Group 3999
@en
P2093
Elisabeth M Paietta
Hajime Uno
Jacob M Rowe
John M Bennett
Larry D Cripe
Mark R Litzow
Rhett P Ketterling
Selina Luger
P2860
P304
P356
10.1182/BLOOD-2010-04-277269
P407
P577
2010-08-17T00:00:00Z